Consumer Defensive -
Household & Personal Products - NYSE - US
$ 64.22
5.16 %
$ 13.8 B
Market Cap
94.44
P/E
1. INTRINSIC VALUE
Balance Sheet
Hims & Hers Health, Inc.
| Current Assets | 396 M |
| Cash & Short-Term Investments | 300 M |
| Receivables | 6.08 M |
| Other Current Assets | 89.5 M |
| Non-Current Assets | 312 M |
| Long-Term Investments | 856 K |
| PP&E | 93 M |
| Other Non-Current Assets | 218 M |
| Current Liabilities | 221 M |
| Accounts Payable | 91.2 M |
| Short-Term Debt | 3.78 M |
| Other Current Liabilities | 126 M |
| Non-Current Liabilities | 9.46 M |
| Long-Term Debt | 9.46 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Hims & Hers Health, Inc.
| Revenue | 1.48 B |
| Cost Of Revenue | 303 M |
| Gross Profit | 1.17 B |
| Operating Expenses | 1.11 B |
| Operating Income | 61.9 M |
| Other Expenses | -64.1 M |
| Net Income | 126 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Hims & Hers Health, Inc.
| Net Income | 126 M |
| Depreciation & Amortization | 17.1 M |
| Capital Expenditures | -41.7 M |
| Stock-Based Compensation | 92.3 M |
| Change in Working Capital | 78.6 M |
| Others | 75.2 M |
| Free Cash Flow | 209 M |
Wall Street Analysts Price Targets
Hims & Hers Health, Inc.
Wall Street analysts predict an average 1-year price target for HIMS of $30.6 , with forecasts ranging from
a
low of
$18 to a high of $68 .
HIMS Lowest Price Target
Wall Street Target
18 USD
-71.97%
HIMS Average Price Target
Wall Street Target
30.6 USD
-52.33%
HIMS Highest Price Target
Wall Street Target
68 USD
5.89%
4. DIVIDEND
ANALYSIS
HIMS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Hims & Hers Health, Inc.
Sold
0-3 MONTHS
39 M USD 6
3-6 MONTHS
50.1 M USD 8
6-9 MONTHS
45.7 M USD 8
9-12 MONTHS
23.3 M USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
132 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Why The Hims & Hers Health Rally Has Room To Run
Hims & Hers reported 2.4 million subscribers in Q1 FY25, a 38% YoY increase from 1.74 million in Q1 FY24. Personalized treatments now make up 58% of the subscriber base, with 70% of new users choosing customized care in Q1. Monthly online revenue per subscriber rose 50% YoY to $84, driven by high adoption of tailored daily treatments.
seekingalpha.com
- 6 days ago
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
HIMS accelerates global growth with ZAVA deal, AI investments and expanded access to obesity care treatments. However, macro challenges may hurt performance.
zacks.com
- 1 week ago
Hims & Hers: Outsized Subscription Growth Is Enviable - Premium Valuations
The bulls have well defended Hims & Hers' recovery from the April 2025 bottom (near to our fair value estimates), thanks to the growing adoption of its personalized healthcare offerings. These have directly triggered the growing subscriber base/ Revenue per Average Subscriber, with the improved manufacturing/ operating scale contributing to the richer profit margins. This is significantly aided by the growing GLP-1 partnership and the regulatory exemption surrounding compounding personalization, lending support to the raised FY2025 guidance and ambitious 2030 targets.
seekingalpha.com
- 1 week ago
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
zacks.com
- 1 week ago
These 2 Growth Stocks Are No-Brainer Buys Right Now
When it comes to investing, sometimes you want to take a big swing. After all, it's not always the number of winners in your portfolio that power your returns, but finding a few stocks that can be massive winners over time.
fool.com
- 1 week ago
2 Reasons To Double Down On Hims & Hers Ahead Of August
I expected Hims & Hers' stock to break $50, and now I'm buckling up for another rally, with EMAs stacked bullishly at the moment. The company's partnership with Novo Nordisk and the ZAVA acquisition for European expansion should drive the next leg of growth. Wegovy sales and potential cheaper Ozempic offerings are set to boost revenue, with subscriber growth and ARPU at record highs despite macro headwinds.
seekingalpha.com
- 1 week ago
Hims & Hers: An Excellent Subscription Business
Hims & Hers offers a high-growth, recurring subscription telehealth business with strong user and revenue growth, expanding into multiple health segments. It is the market leader in telehealth easily outpacing its competition. The trend among millenials and Gen Z patients towards digital health should ensure Hims sustaining its pole position.
seekingalpha.com
- 1 week ago
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
zacks.com
- 2 weeks ago
These 24 Stocks Are Ripe for a Short Squeeze
With the way negative stock market sentiment has piled up recently, short squeezes have generated some massive returns.
schaeffersresearch.com
- 2 weeks ago
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
Hims & Hers' 38.4% subscriber growth and $576.4 million online revenues highlight the power of its personalized subscription model.
zacks.com
- 2 weeks ago
Hims & Hers: The ZAVA Acquisition Catapults Growth In Europe's Weight-Loss Market
Hims & Hers Health's acquisition of ZAVA fast-tracks its entry into Europe's weight-loss market, expanding its subscriber base by 54%. The deal is attractively priced, non-dilutive, and leverages ZAVA's established infrastructure and regulatory expertise across four major European countries. Hims' proven GLP-1 strategy in the U.S. positions it to address Europe's unmet demand for affordable, personalized weight-loss solutions via telehealth.
seekingalpha.com
- 2 weeks ago
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $55.25, denoting a -2.83% change from the preceding trading day.
zacks.com
- 2 weeks ago
8. Profile
Summary
Hims & Hers Health, Inc. HIMS
COUNTRY
US
INDUSTRY
Household & Personal Products
MARKET CAP
$ 13.8 B
Dividend Yield
0.00%
Description
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Contact
2269 Chestnut Street, San Francisco, CA, 94123
https://www.forhims.com
IPO
Date
Sept. 13, 2019
Employees
1637
Officers
Mr. Andrew Dudum
Co-Founder, Chairman & Chief Executive Officer
Ms. Soleil Teubner Boughton J.D.
Chief Legal Officer & Corporate Secretary
Mr. Nader Kabbani
Chief Operations Officer
Ms. Irene A. Becklund
Senior Vice President, Controller & Principal Accounting Officer
Mr. Mohamed ElShenawy
Chief Technology Officer
Dr. Patrick Carroll M.D.
Chief Medical Officer & Director
Ms. Khobi Brooklyn
Chief Communications Officer
Mr. Oluyemi Okupe
Chief Financial Officer
Mr. Mike Chi
Chief Commercial Officer
Dr. Peter Stahl M.D.
Senior Vice President of Men's Reproductive & Sexual Health